Kyverna Therapeutics, Inc.
KYTX
$8.17
$0.091.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | 129.00% | |||
| Gross Profit | -- | -129.00% | |||
| SG&A Expenses | 30.76% | 21.86% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.38% | 5.31% | |||
| Operating Income | 4.38% | -5.31% | |||
| Income Before Tax | 3.55% | -5.09% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 3.55% | -5.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.55% | -5.09% | |||
| EBIT | 4.38% | -5.31% | |||
| EBITDA | 4.62% | 46.87% | |||
| EPS Basic | 4.29% | 18.00% | |||
| Normalized Basic EPS | 4.28% | 18.00% | |||
| EPS Diluted | 4.29% | 18.00% | |||
| Normalized Diluted EPS | 4.28% | 18.00% | |||
| Average Basic Shares Outstanding | 0.77% | 28.16% | |||
| Average Diluted Shares Outstanding | 0.77% | 28.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||